Ligand Pharmaceuticals LGND Captisol — Asset impairment charges
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: Ligand Pharmaceuticals’s 10-K, filed February 27, 2026.
- Filed
- Feb 27, 2026, 4:02 PM EST
- Fiscal year
- FY2025
- Accession
- 0000886163-26-000006
We recorded a $9.8 million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December 31, 2022. As of December 31, 2022, the remaining right of use asset balance was $4.0 million which will be amortized straight-line over the remaining 6 years lease term. During the years ended December 31, 2025, 2024 and 2023, no impairment to this asset group was recorded as there were no indicators of impairment. As of December 31, 2025 and 2024, the remaining right of use asset balance is $2.0 million and $2.7 million, respectively.
Item 8. Consolidated Financial Statements and Supplementary Data
FAQ
- What is Ligand Pharmaceuticals's captisol — asset impairment charges?
- Ligand Pharmaceuticals (LGND) reported captisol — asset impairment charges of $0 in Q4 2025.
- What does captisol — asset impairment charges mean?
- The total expense recognized to reduce the carrying value of long-lived assets within the Captisol segment when their book value is deemed unrecoverable. High or frequent charges may indicate structural issues, technological obsolescence, or poor capital allocation within the segment.
Ask your AI about Ligand Pharmaceuticals's captisol — asset impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
